The Utilization of Glucagon-like Peptide 1 Agonists and Risk of Following External Eye Diseases in Type 2 Diabetes Mellitus Individuals: A Population-Based Study

The Utilization of Glucagon-like Peptide 1 Agonists and Risk of Following External Eye Diseases in Type 2 Diabetes Mellitus Individuals: A Population-Based Study

The glucagon-like peptide 1 (GLP-1) agonist showed anti-hyperglycemic and anti-inflammatory effects, which may retard the risk of external eye disease. The protective effect of GLP-1 agonist and dry eye disease (DED) was found, while the relationship between GLP-1 agonist and other corneal diseases...

Full description

Bibliographic Details
Main Authors: Ying-Chi Fan, Shu-Yen Peng, Chao-Kai Chang, Chia-Yi Lee, Jing-Yang Huang, Ming-Ju Hsieh, Shun-Fa Yang
Format: Article
Language:English
Published: MDPI AG 2023-10-01
Series:Healthcare
Subjects:
GLP-1 agonists
dry eye disease
superficial keratitis
epidemiology
age
Online Access:https://www.mdpi.com/2227-9032/11/20/2749

Similar Items

Similar Items